This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective was to assess the cost-effectiveness of zoledronic acid for the prevention of fractures in postmenopausal women, with hormone receptor positive, early breast cancer (stages I to IIIa), who were being treated with aromatase inhibitors.
Interventions
Two interventions were compared against no zoledronic acid. All patients were given adjuvant letrozole at 2.5mg daily for five years.
The first intervention was six-monthly intravenous zoledronic acid (4mg), beginning at the same time as the adjuvant letrozole. The second intervention was zoledronic acid delayed until the patient's bone mineral density T-score decreased to more than two standard deviations below normal; until they had a non-traumatic fracture; or until they were found to have an asymptomatic fracture upon assessment three years after starting letrozole.
Location/setting
UK/primary care.
Methods

Analytical approach:
A Markov model was developed to combine the cost and effectiveness data from published sources. The model's cycle length was one year and the time horizon was the patient's lifetime. The authors stated that the perspective was that of the UK NHS.
Effectiveness data:
The effectiveness data for zoledronic acid in retaining bone mineral density (BMD) was from a three-year interim analysis of several published trials. After treatment ceased, zoledronic acid was assumed to have no further effect. BMD without treatment was from a bone subanalysis of a published trial. Mortality in the first five years was from standard sources, and incorporated additional mortality due to hip fracture. After five years, mortality was from published cancer survival data. The main clinical effectiveness estimate was the fracture risk and these data were from published studies.
